Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases-Reference-Cited by-同舟云学术

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases

Published:2021-05-11 Issue:10 Volume:80 Page:1357-1359
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Spiera Robert,Jinich Sarah^ORCID,Jannat-Khah Deanna

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. COVID-19 vaccination and antirheumatic therapy;Arnold;Rheumatology,2021

2. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases;Baker;Clin Exp Immunol,2020

3. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?;Houot;Eur J Cancer,2020

4. Rituximab treatment results in impaired secondary humoral immune responsiveness;van der Kolk;Blood,2002

5. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients;Frontiers in Immunology;2024-07-26

2. A Case Report and Literature Review of a Triple-Vaccinated, Rituximab-Treated Systemic Lupus Erythematosus patient with COVID-19 pneumonia;ARP Rheumatology;2024-06-30

3. Harnessing immunity: Immunomodulatory therapies in COVID-19;World Journal of Virology;2024-06-25

4. Serological response to SARS‐CoV‐2 vaccination in patients with immunobullous diseases;JEADV Clinical Practice;2024-06-19

5. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases;JCI Insight;2024-06-04